新型设计药物bk-MBDB和bk-MDEA在人尿液中代谢物的测定。
Determination of the metabolites of the new designer drugs bk-MBDB and bk-MDEA in human urine.
作者信息
Zaitsu Kei, Katagi Munehiro, Kamata Hiroe T, Kamata Tooru, Shima Noriaki, Miki Akihiro, Tsuchihashi Hitoshi, Mori Yasushige
机构信息
Forensic Science Laboratory, Osaka Prefectural Police Headquarters, 1-3-18, Hommachi, Chuo-ku, Osaka 541-0053, Japan.
出版信息
Forensic Sci Int. 2009 Jul 1;188(1-3):131-9. doi: 10.1016/j.forsciint.2009.04.001. Epub 2009 Apr 29.
This is the first report on identifying the specific metabolites of the new designer drugs 2-methylamino-1-(3,4-methylenedioxyphenyl)butan-1-one (bk-MBDB) and 2-ethylamino-1-(3,4-methylenedioxyphenyl)propan-1-one (bk-MDEA) in human urine using synthesized standards. Based on GC/MS and LC/MS, we identified N-dealkylation, demethylenation followed by O-methylation, and beta-ketone reduction as their major metabolic pathways. The quantitative analyses by LC/MS revealed that both demethylenation followed by O-methylation and beta-ketone reduction were superior to N-dealkylation and that both bk-MBDB and bk-MDEA were mainly metabolized into their corresponding 4-hydroxy-3-methoxy metabolites (4-OH-3MeO metabolites). After hydrolysis, the concentrations of 4-OH-3MeO metabolites and 3-hydroxy-4-methoxy metabolites of both bk-MBDB and bk-MDEA dramatically increased, suggesting that the metabolites mainly exist as their conjugates.
这是首篇关于使用合成标准品鉴定新型设计药物2-甲基氨基-1-(3,4-亚甲二氧基苯基)丁-1-酮（bk-MBDB）和2-乙氨基-1-(3,4-亚甲二氧基苯基)丙-1-酮（bk-MDEA）在人尿液中特定代谢物的报告。基于气相色谱/质谱联用仪（GC/MS）和液相色谱/质谱联用仪（LC/MS），我们确定了N-脱烷基化、亚甲二氧基脱甲基后进行O-甲基化以及β-酮还原为它们的主要代谢途径。液相色谱/质谱联用仪的定量分析表明，亚甲二氧基脱甲基后进行O-甲基化和β-酮还原均优于N-脱烷基化，并且bk-MBDB和bk-MDEA均主要代谢为其相应的4-羟基-3-甲氧基代谢物（4-OH-3MeO代谢物）。水解后，bk-MBDB和bk-MDEA的4-OH-3MeO代谢物和3-羟基-4-甲氧基代谢物的浓度显著增加，这表明这些代谢物主要以其共轭物形式存在。
Zotero 插件